Claims

1. A coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier.

2. A coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier according to claim 1, wherein the carrier is selected from the group consisting of polyvinylpyrrolidone, silicium dioxide, mannitol, lactose, methylcellulose and cyclodextrin.

3. The coprecipitate according to claim 1, wherein it is the coprecipitate of amorphous rosiglitazone maleate with polyvinylpyrrolidone.

4. The coprecipitate according to claim 1, wherein it is the coprecipitate of amorphous rosiglitazone maleate with silicon dioxide.

5. The coprecipitate according to claim 1, wherein it is the coprecipitate of amorphous rosiglitazone maleate with mannitol.

6. The coprecipitate according to claim 1, wherein it is the coprecipitate of amorphous rosiglitazone maleate with lactose.

7. The coprecipitate according to claim 1, wherein it is the coprecipitate of amorphous rosiglitazone maleate with methylcellulose.

8. The coprecipitate according to claim 1, wherein it is the coprecipitate of amorphous rosiglitazone maleate with gamma-cyclodextrin.

9. A coprecipitate according to claims 1 to 8, wherein the ratio of amorphous rosiglitazone maleate to a pharmaceutically acceptable carrier ranges from 1 : 1 to 1 : 20.

10. A coprecipitate according to claims 1 to 8, wherein the ratio of amorphous rosiglitazone maleate to a pharmaceutically acceptable carrier ranges from 1 : 1 to 1 : 4.

11. A process for the preparation of a coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier, which comprises the steps of:
    a) dissolving rosiglitazone maleate in an organic solvent or in an aqueous solution of organic solvent,
    b) adding pharmaceutically acceptable carrier,
    c) spray-drying the obtained solution.

12. The process according to claim 11, wherein a pharmaceutically acceptable carrier is selected from the group consisting of polyvinylpyrrolidone, silicon dioxide, mannitol, lactose, methylcellulose and cyclodextrin.

13. The process according to claim 11, wherein an organic solvent is selected from the group consisting of ethanol and acetone.

14. The process according to claim 11, wherein the range of organic solvent to water is from about 9 : 1 to about 1 : 1 (V / V).

15. The process according to claims 11, wherein the range of organic solvent to water is from about 9 : 1 to about 7 : 3 (V / V)

16. A process for the preparation of a coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier, which comprises the steps of:
    a) dissolving rosiglitazone (base) in an organic solvent
    b) adding maleic acid and stirred the mixture to obtain a clear solution,
    c) adding pharmaceutically acceptable carrier,

d) spray-drying the obtained solution.

17. A pharmaceutical composition comprising a coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier and other excipients.

18. A coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier according to claims 1 to 10, for use in the treatment and / or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

19. The use of a coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier according to claims 1 to 10, for the manufacture of a medicament for the treatment and / or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

20. A solid solution of rosiglitazone maleate with a pharmaceutically acceptable carrier.

21. A solid solution according to claim 20, wherein the pharmaceutically acceptable carrier is selected from polyethylene glycols between 4000 to 40.000 of average mol. weight.

22. A process for the preparation of a solid solution of rosiglitazone maleate with a pharmaceuticall acceptable carrier, which comprises the steps of:

a) melting rosilitazone maleate or optionally rosiglitazone and maleic acid with a pharmaceutically acceptable carrier to form a melt
b) cooling the obtained melted solution

23. The process according to claim 22, wherein a pharmaceutically acceptable carrier is selected from polyethylene glycols between 4000 to 40.000 of average mol. weight.

24. A pharmaceutical composition comprising a solid solution of rosiglitazone maleate with a pharmaceutically acceptable carrier and other excipients.